NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Forecast, Price & News $0.61 0.00 (0.00%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$0.60▼$0.6350-Day Range$0.51▼$1.0552-Week Range$0.51▼$4.37Volume377,861 shsAverage Volume4.83 million shsMarket Capitalization$116.01 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Nektar Therapeutics MarketRank™ ForecastAnalyst RatingReduce1.80 Rating ScoreUpside/Downside391.6% Upside$3.00 Price TargetShort InterestHealthy3.57% of Shares Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.31Based on 4 Articles This WeekInsider TradingSelling Shares$26,174 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.00) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector176th out of 964 stocksPharmaceutical Preparations Industry64th out of 439 stocks 2.9 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Nektar Therapeutics has a forecasted upside of 391.6% from its current price of $0.61.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.57% of the outstanding shares of Nektar Therapeutics have been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 5.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 1.8 News and Social Media Coverage News SentimentNektar Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,174.00 in company stock.Percentage Held by InsidersOnly 3.07% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions82.20% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nektar Therapeutics (NASDAQ:NKTR) StockNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Read More NKTR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTR Stock News HeadlinesSeptember 21, 2023 | benzinga.comDirector at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 SharesSeptember 21, 2023 | benzinga.comNektar Therapeutics Board Member Awarded $59K Worth of Stock OptionsSeptember 27, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 13, 2023 | markets.businessinsider.comNektar Therapeutics Reports Promising Data From Phase 1b Study Of RezpegaldesleukinSeptember 7, 2023 | finance.yahoo.comWhy Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?September 6, 2023 | finance.yahoo.comNektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13thAugust 18, 2023 | gurufocus.comRA Capital Management, L.P. Acquires Significant Stake in Nektar TherapeuticsAugust 9, 2023 | finance.yahoo.comNektar Therapeutics (NKTR) Q2 Loss Narrows, Sales MissSeptember 27, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 8, 2023 | markets.businessinsider.comNektar Therapeutics Q2 Loss decreases, beats estimatesAugust 8, 2023 | finance.yahoo.comNektar Therapeutics Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comMizuho Reiterates Nektar Therapeutics (NKTR) Neutral RecommendationAugust 7, 2023 | proactiveinvestors.comNektar stock soars on new data for rezpeg after Eli Lilly got it wrongAugust 7, 2023 | benzinga.comWhy Is Nektar Therapeutics Stock Surging Today?August 7, 2023 | reuters.comNektar Therapeutics sues Eli Lilly over autoimmune disease treatmentAugust 7, 2023 | finance.yahoo.comNektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & CompanyAugust 1, 2023 | finance.yahoo.comNektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial MarketsJuly 16, 2023 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the companyJuly 11, 2023 | gurufocus.comCitadel Advisors LLC Acquires Significant Stake in Nektar TherapeuticsJuly 1, 2023 | finanznachrichten.deNektar Regains Full Rights Of REZPEG From Eli Lilly, Plans To Initiate Phase 2b StudyJune 12, 2023 | finance.yahoo.comNektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 8, 2023 | finance.yahoo.comWhy Is Nektar (NKTR) Down 19.7% Since Last Earnings Report?June 8, 2023 | finance.yahoo.comInvestors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) TunnelMay 26, 2023 | bizjournals.comHoward Robin seeks another turnaround at NektarMay 11, 2023 | msn.comJefferies Upgrades Nektar Therapeutics (NKTR)May 10, 2023 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call TranscriptMay 10, 2023 | markets.businessinsider.comJefferies upgrades Nektar Therapeutics (NKTR) to a HoldSee More Headlines Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Company Calendar Last Earnings8/08/2023Today9/27/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees216Year Founded1990Price Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+391.6%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-368,200,000.00 Net Margins-349.75% Pretax Margin-346.47% Return on Equity-67.03% Return on Assets-32.01% Debt Debt-to-Equity RatioN/A Current Ratio8.70 Quick Ratio8.29 Sales & Book Value Annual Sales$87.74 million Price / Sales1.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.31Miscellaneous Outstanding Shares190,119,000Free Float184,282,000Market Cap$116.01 million OptionableOptionable Beta1.00 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Howard W. Robin (Age 70)CEO, Pres & Director Comp: $1.83MMr. Mark A. Wilson (Age 51)Sr. VP, Chief Legal Officer & Sec. Comp: $749.99kDr. Jonathan Zalevsky Ph.D. (Age 48)Sr. VP & Chief R&D Officer Comp: $1.25MMs. Sandra A. Gardiner (Age 57)Chief Financial Officer Vivian WuDirector of Investor Relations & Corp. AffairsMr. Robert BacciSr. VP of HR & Facilities OperationsMs. Jennifer RuddockChief Bus. OfficerDr. Mary Tagliaferri L.Ac. (Age 57)M.D., Chief Medical Officer Dr. Loui T. MadakamutilVP and Head of Discovery & ResearchMore ExecutivesKey CompetitorsOmerosNASDAQ:OMERAssembly BiosciencesNASDAQ:ASMBCumberland PharmaceuticalsNASDAQ:CPIXOrganigramNASDAQ:OGIProQR TherapeuticsNASDAQ:PRQRView All CompetitorsInsiders & InstitutionsBarclays PLCSold 95,422 shares on 9/21/2023Ownership: 0.030%Myriam CuretSold 4,359 sharesTotal: $3,007.71 ($0.69/share)Howard W RobinSold 19,998 sharesTotal: $15,598.44 ($0.78/share)Jonathan ZalevskySold 9,703 sharesTotal: $7,568.34 ($0.78/share)Public Employees Retirement System of OhioBought 123,860 shares on 8/15/2023Ownership: 0.164%View All Insider TransactionsView All Institutional Transactions NKTR Stock - Frequently Asked Questions Should I buy or sell Nektar Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" NKTR shares. View NKTR analyst ratings or view top-rated stocks. What is Nektar Therapeutics' stock price forecast for 2023? 5 brokers have issued 12-month price objectives for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $1.00 to $6.00. On average, they anticipate the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 391.6% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. How have NKTR shares performed in 2023? Nektar Therapeutics' stock was trading at $2.26 on January 1st, 2023. Since then, NKTR stock has decreased by 73.0% and is now trading at $0.6102. View the best growth stocks for 2023 here. When is Nektar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our NKTR earnings forecast. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) released its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03. The biopharmaceutical company earned $20.50 million during the quarter, compared to analyst estimates of $20.94 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 67.03% and a negative net margin of 349.75%. During the same quarter in the prior year, the business posted ($0.85) EPS. What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY). What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Deep Track Capital LP (9.45%), Monaco Asset Management SAM (4.89%), BlackRock Inc. (4.55%), Acadian Asset Management LLC (2.32%), Renaissance Technologies LLC (2.16%) and Assenagon Asset Management S.A. (1.10%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $0.61. How much money does Nektar Therapeutics make? Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $116.01 million and generates $87.74 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. How many employees does Nektar Therapeutics have? The company employs 216 workers across the globe. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300. This page (NASDAQ:NKTR) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.